EPO: Enlarged Board endorses video hearings in appeal proceedings

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO: Enlarged Board endorses video hearings in appeal proceedings

Sponsored by

inspicos-400px recrop.jpg
rythik-ajkmy81ivus-unsplash.jpg

Jakob Pade Frederiksen of Inspicos P/S explains the EBA’s G 1/21 decision

On October 28 2021, the Enlarged Board of Appeal (EBA) issued its reasons for decision G 1/21 on the legality of the conduct of oral proceedings in the form of a videoconference (ViCo). The decision lays down that during a general emergency impairing the parties’ possibilities to attend in-person oral proceedings at the EPO premises, the conduct of oral proceedings before the boards of appeal by way of ViCo is compatible with the European Patent Convention even without the consent of all parties to the proceedings. The decision is specifically concerned with oral proceedings at the appeal stage only and is therefore not immediately applicable to oral proceedings at the first instance.

Regarding the parties’ right to oral proceedings enshrined in Article 116 EPC, the EBA holds that the term ‘oral proceedings’ is not limited to the specific form that was known at the time the EPC was drawn up, and that it would be at odds with the object and purpose of the EPC if the intention of the legislator was to exclude future formats for oral proceedings that might be made possible by technological progress.

In the context of the parties’ fundamental right to be heard pursuant to Article 113 EPC, the EBA expresses the view that in-person oral proceedings for now are the optimum format, even though the right to be heard or the right to fair proceedings, according to the EBA, can in fact be respected in the ViCo format. The in-person format should, however, be the default option. 

With respect to the conduct of oral proceedings by way of ViCo in the absence of the parties’ consent, the EBA notes that there must be circumstances that justify not holding the oral proceedings in person. Such circumstances may, e.g. relate to impairments affecting the parties’ ability to travel in case of a pandemic. 

Even though decision G 1/21 specifically addresses oral proceedings in appeal, there seems to be nothing that suggests that the reasons of the EBA would not be applicable to oral proceedings within the meaning of Article 116 EPC in general. It remains to be seen if the EPO adopts the findings of G 1/21 in respect of oral proceedings before the departments of first instance.

 

Jakob Pade Frederiksen

Partner, Inspicos P/S

E: jpf@inspicos.com

 

more from across site and SHARED ros bottom lb

More from across our site

Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
News of a breakaway firm launching in Germany and a spike in vaccine-related patent applications were also among the top talking points
A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
Gift this article